BRCA1/2 and clinical outcome in a monoinstitutional cohort of women with hereditary breast cancer

被引:12
作者
Sambiasi, Domenico [1 ]
Lambo, Rossana [1 ]
Pilato, Brunella [1 ]
Tommasi, Stefania [1 ]
Trojano, Giuseppe [1 ]
Kardhashi, Anila [1 ]
Digennaro, Maria [1 ]
Trojano, Vito [1 ]
Simone, Gianni [1 ]
Paradiso, Angelo [1 ]
机构
[1] Natl Canc Res Ctr Giovanni Paolo II, I-70124 Bari, Italy
关键词
BRCA1; BRCA2; follow-up; outcome; MUTATION STATUS; OVARIAN-CANCER; FAMILY-HISTORY; RISKS; SURVIVAL; CARRIERS; SURGERY; SERIES;
D O I
10.3892/or.2013.2802
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The clinical outcome of BRCA mutation carriers and non-carriers still remains a topic of discussion. In order to interpret controversial data, in the present study, we analyzed a large consecutive monoinstitutional series of breast cancer patients and relatives with familial features carrying or not carrying BRCA mutations. The intense research in recent years regarding the clinical genetics of patients with breast or ovarian cancer and their relatives has allowed the organization of a unique database comprising anamnestic, clinical, pathological and molecular data. Families with two or more cases of breast cancer under the age of 50 years, or with three cases at any age, were identified. From June, 2003 to June, 2010, a total of 202 patients (136 probands + 66 relatives) from 45 families were included in the analysis. A total of 136 (49 carrier and 87 non-carrier) cases had a cancer diagnosis at the time of their genetic testing. Twenty and 24 events were observed in the carrier and control group, respectively. The 10-year disease-free suvival rate was 57% for patients in the control group compared with 50% for patients carrying a BRCA mutation (P=0.15 by log-rank test). Finally, 66 (32 genetic and 34 control) cases were unaffected at the time of molecular analysis, and 6 new cases of cancer were observed in the carriers, while no new cases were detected in the control cohort. Thus, at age 50, 40% of carriers had a high risk of disease (P=0.0069 by log-rank test). Our data support the hypothesis that the presence of BRCA mutations does not alter the clinical outcome for hereditary breast cancer patients. Conversely, BRCA mutations are proven to be crucial for prediction of risk in healthy relatives from carrier families.
引用
收藏
页码:365 / 369
页数:5
相关论文
共 31 条
  • [1] Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers
    Adem, C
    Reynolds, C
    Soderberg, CL
    Slezak, JM
    McDonnell, SK
    Sebo, TJ
    Schaid, DJ
    Myers, JL
    Sellers, TA
    Hartmann, LC
    Jenkins, RB
    [J]. CANCER, 2003, 97 (01) : 1 - 11
  • [2] Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials
    Albain, K.
    Anderson, S.
    Arriagada, R.
    Barlow, W.
    Bergh, J.
    Bliss, J.
    Buyse, M.
    Cameron, D.
    Carrasco, E.
    Clarke, M.
    Correa, C.
    Coates, A.
    Collins, R.
    Costantino, J.
    Cutter, D.
    Cuzick, J.
    Darby, S.
    Davidson, N.
    Davies, C.
    Davies, K.
    Delmestri, A.
    Di Leo, A.
    Dowsett, M.
    Elphinstone, P.
    Evans, V.
    Ewertz, M.
    Gelber, R.
    Gettins, L.
    Geyer, C.
    Goldhirsch, A.
    Godwin, J.
    Gray, R.
    Gregory, C.
    Hayes, D.
    Hill, C.
    Ingle, J.
    Jakesz, R.
    James, S.
    Kaufmann, M.
    Kerr, A.
    MacKinnon, E.
    McGale, P.
    McHugh, T.
    Norton, L.
    Ohashi, Y.
    Paik, S.
    Pan, H. C.
    Perez, E.
    Peto, R.
    Piccart, M.
    [J]. LANCET, 2012, 379 (9814) : 432 - 444
  • [3] [Anonymous], 2002, Statistical Models and Methods for Lifetime Data
  • [4] Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history:: A combined analysis of 22 studies
    Antoniou, A
    Pharoah, PDP
    Narod, S
    Risch, HA
    Eyfjord, JE
    Hopper, JL
    Loman, N
    Olsson, H
    Johannsson, O
    Borg, Å
    Pasini, B
    Radice, P
    Manoukian, S
    Eccles, DM
    Tang, N
    Olah, E
    Anton-Culver, H
    Warner, E
    Lubinski, J
    Gronwald, J
    Gorski, B
    Tulinius, H
    Thorlacius, S
    Eerola, H
    Nevanlinna, H
    Syrjäkoski, K
    Kallioniemi, OP
    Thompson, D
    Evans, C
    Peto, J
    Lalloo, F
    Evans, DG
    Easton, DF
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 72 (05) : 1117 - 1130
  • [5] Breast Canc Linkage Consortium, 1999, JNCI-J NATL CANCER I, V91, P1310
  • [6] Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases
    Brekelmans, C. T. M.
    Tilanus-Linthorst, M. M. A.
    Seynaeve, C.
    Van der Ouweland, A.
    Menke-Pluymers, M. B. E.
    Bartels, C. C. M.
    Kriege, M.
    van Geel, A. N.
    Burger, C. W.
    Eggermont, A. M. M.
    Meijers-Heijboer, H.
    Klijn, J. G. M.
    [J]. EUROPEAN JOURNAL OF CANCER, 2007, 43 (05) : 867 - 876
  • [7] Brose MS, 2002, J NATL CANCER I, V94, P1365, DOI 10.1093/jnci/94.18.1365
  • [8] Role of BRCA2 mutation status on overall survival among breast cancer patients from Sardinia
    Budroni, Mario
    Cesaraccio, Rosaria
    Coviello, Vincenzo
    Sechi, Ornelia
    Pirino, Daniela
    Cossu, Antonio
    Tanda, Francesco
    Pisano, Marina
    Palomba, Grazia
    Palmieri, Giuseppe
    [J]. BMC CANCER, 2009, 9
  • [9] Chappuis PO, 2000, SEMIN SURG ONCOL, V18, P287, DOI 10.1002/(SICI)1098-2388(200006)18:4<287::AID-SSU3>3.0.CO
  • [10] 2-5